Daily Newsletter

30 October 2023

Daily Newsletter

30 October 2023

FDA warns of infection risks from over-the-counter eye drops 

Patients who have used the products should consult their healthcare provider or seek medical advice.

Vishnu Priyan October 30 2023

The US Food and Drug Administration (FDA) has issued a warning against the use of 26 over-the-counter eye drop products.

The regulator asked consumers not to buy and to immediately stop using the products due to the risk of infections that could lead to partial vision loss or even blindness.

Patients who have used the products should consult their healthcare provider or seek medical advice. 

The medicines are offered under the brand names CVS Health, Leader (Cardinal Health), Rite Aid, Rugby (Cardinal Health), Target Up&Up and Velocity Pharma.

On 25 October 2023, the FDA recommended manufacturers to recall all the lots after regulatory investigators detected unsanitary conditions at manufacturing sites. 

The investigators found positive results from bacterial tests conducted on samples taken at critical drug manufacturing areas. 

The regulator asked consumers to carry out product disposals properly.

In a press statement, the FDA noted: “CVS, Rite Aid and Target are removing the products from their store shelves and websites. 

“Products branded as Leader, Rugby and Velocity may still be available to purchase in stores and online and they should not be purchased.”

The FDA has not yet received reports of adverse events linked to the products' usage.

Analyzing the key M&A trends in the Contract Manufacturing industry

Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close